[{"orgOrder":0,"company":"Meridian Medical Technologies","sponsor":"Public Health Agency of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Meridian Medical Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Meridian Medical Technologies \/ Public Health Agency of Canada","highestDevelopmentStatusID":"15","companyTruncated":"Meridian Medical Technologies \/ Public Health Agency of Canada"},{"orgOrder":0,"company":"Meridian Medical Technologies","sponsor":"SIGA Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Tecovirimat","moa":"Envelope phospholipase F13 (p37)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Meridian Medical Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Meridian Medical Technologies \/ SIGA Technologies","highestDevelopmentStatusID":"15","companyTruncated":"Meridian Medical Technologies \/ SIGA Technologies"},{"orgOrder":0,"company":"Meridian Medical Technologies","sponsor":"ASPR","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Atropine","moa":"||mAChRs","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Meridian Medical Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Meridian Medical Technologies \/ ASPR","highestDevelopmentStatusID":"15","companyTruncated":"Meridian Medical Technologies \/ ASPR"}]

Find Clinical Drug Pipeline Developments & Deals by Meridian Medical Technologies

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : SIGA will lead international promotions for oral TPOXX, an FDA-approved drug for smallpox, while maintaining its contractual relationship with Meridian to ensure continuity for key customers.

                          Product Name : Tpoxx

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 04, 2024

                          Lead Product(s) : Tecovirimat

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : SIGA Technologies

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Under the agreement, Meridian will supply DuoDote to the Administration for Strategic Preparedness and Response within the United States. DuoDote® is an FDA-approved dual-chamber autoinjector (atropine and pralidoxime chloride) chemical nerve agent anti...

                          Product Name : DuoDote

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          November 14, 2023

                          Lead Product(s) : Atropine,Pralidoxime Chloride

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Approved FDF

                          Sponsor : ASPR

                          Deal Size : $9.9 million

                          Deal Type : Agreement

                          blank

                          03

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Public Health Agency of Canada has contracted Meridian Medical Technologies for the purchase up to approximately $33 million of oral TPOXX® within five years. TPOXX® is an orally administered antiviral drug for the treatment of human smallpox disease c...

                          Product Name : Tpoxx

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 13, 2021

                          Lead Product(s) : Tecovirimat

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Public Health Agency of Canada

                          Deal Size : $3.4 million

                          Deal Type : Collaboration

                          blank